Hints and tips:
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...Its — untested — argument is that Amgen could use rebates on its blockbusters to encourage insurers and pharmacy benefit managers to favour Horizon’s drugs....
...Big Pharma has always bought out small drug developers to restock its pipelines. Some emerging health science companies aspire to be the next Amgen, which has a market capitalisation of $120bn....
...Pao, speaking at the Financial Times US Pharma and Biotech Summit in New York, said he was confident the FTC would approve the Seagen deal....
...Amgen and Horizon indicated they would try to complete the deal by fighting the FTC in court....
...The FTC attempted to block Amgen’s $28.3bn takeover of Horizon Therapeutics. Barriers to M&A are going to make it harder for pharma companies to replenish drug pipelines....
...In a quieter deal environment, this deal underscores that Big Pharma has the means to make big bets....
...In Amgen’s case, the FTC argued that the Big Pharma group could get buyers to favour Horizon’s drugs by bundling them with its own best medicines....
...“I’m glad the FTC is looking at this,” Schleifer told the Financial Times US pharma and biotech summit in New York....
...The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said...
...The FTC case against Amgen-Horizon is also a break from the past. Amgen wants to acquire Horizon to gain two blockbuster drugs that currently face little competition....
...Pfizer’s chief executive Albert Bourla said the pharma group was “deploying its financial resources to advance the battle against cancer”....
...PwC forecasts pharma and life sciences deals worth $225bn to $275bn in 2023, compared with $137.8bn in 2022 — a figure that does not include the value of the Amgen deal....
...Looming over the horizon is the holiday weekend in late February that typically marks the beginning of the US spring break travel season....
...It is not all sunny skies, however, with geopolitics and local US issues both clouding the horizon....
...Shares in Biogen and Eisai surged on Wednesday after the pharma groups said they would apply for regulatory approval for a new Alzheimer’s drug following a late-stage clinical trial that showed it slowed...
...Horizon is working with the US Food and Drug Administration to find another contract manufacturer....
...He trades a lot with major pharma....
...have made to diversify beyond their traditional business — in products from vapes and e-cigarettes to oral nicotine pouches — but Philip Morris can rightly claim to have taken the lead in broadening its horizons...
...With a vaccine on the horizon, it is tempting to believe that the end of the pandemic is in sight. But there is a long road ahead....
...What else is on the horizon for you? Inclusivity. Embracing people of all different backgrounds regardless of race, colour, creed, size. Our Adaptive line [for children with disabilities]....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...They have huge ambitions but are willing to view their efforts in this space over a 10-year horizon — and possibly longer.”...
...Our 10% WACC remains a premium to our mid-cap pharma peer average 8.6% which reflects our view of increased risk around single product execution....
...Campari will be hard hit by COVID-19 due to high On Trade exposure, especially in core markets of Italy and the USA....
International Edition